Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4547 with cisplatin and capecitabine in advanced solid tumors and FGFR2-positive gastro-oesophageal cancer
ISRCTN66171897Phase 2Terminated
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Jan 2012
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of fexagratinib in Nonhematologic neoplasms, esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma and 2 more (3 arms), sponsored by NHS Greater Glasgow and Clyde. Primary endpoints: Safety and toxicity and Progression-free survival. Started Jan 2012; status: terminated.
02
Drugs
fexagratinib
03
Conditions
Nonhematologic neoplasmsesophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinomagastric adenocarcinomaGastroesophageal carcinoma (GEC)
Beyond the preview
Go deeper on ISRCTN66171897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN66171897.